Quest Diagnostics Prioritizes Patients With Risk Of Coronavirus
Zacks Investment Research | Mar 22, 2020 10:31PM ET
Quest Diagnostics (NYSE:DGX) announced that through its "Peace of Mind" program, it will provide special VIP-level access to its 2,250 patient service centers across the United States for people, who are most susceptible to COVID-19.
The initiative will make the company one of the active players that are combating the public health crisis.
More About the Program
Through the initiative, people, who age 60 years and above or have other conditions known to elevate the risk of exposure to COVID-19, will be granted special access to the centers during the first hour of each day after each center opens. Patients have the option to schedule an appointment beforehand or they can even show up without an appointment in centers that allow walk-ins.
Notably, Quest Diagnostics’ patient service centers are not admitting patients suspected or confirmed to be affected with coronavirus. The centers are also not directly collecting samples for COVID-19 testing. However, the company is accepting and conducting testing on COVID-19 specimens submitted by healthcare providers across the United States.
Moreover, Quest Diagnostics has implemented other precautionary measures to ensure that all patients have access to a safe and healthy environment. Moreover, the company is promoting social distancing by restricting the number of chairs in patient service centers to no more than 10. It is also distributing hand-buzzers to patients after they register, enabling them to return to their vehicles if they want until they are buzzed for the appointment. The company is also staffing the doors of many centers with an escort to allow access.
The program has started in select locations from Mar 21 and will be available nationwide from Mar 23.
Recent Developments
Lately, Quest Diagnostics has been taking major strides in battling the coronavirus pandemic.
The company recently announced plans to launch a coronavirus (COVID-19) test service. Notably, the collection of specimens has already started on Mar 9, 2020. Through the latest service, the company will cater to the testing requirements of patients in the United States. The test facilitates the presumptive detection of nucleic acid in respiratory samples of patients who meet the clinical criteria of the Centers for Disease Control and Prevention for COVID-19 testing.
Price Performance
In the past year, the stock has lost 15% compared with a 23.9% decline of its Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.